Ebastine for diarrhea-predominant IBS
Part of Digestive system clinical trials.
This trial tests whether ebastine, an allergy medicine, can help relieve symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D). If you have IBS-D and are at least 18, this study may offer a new option to manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have diarrhea-predominant IBS (diagnosed using Rome IV criteria).
- You must not have any 'alarm' signs such as unexplained weight loss or blood in your stool.
- You cannot have had major stomach or intestinal surgery in the past.
- You cannot be pregnant or breastfeeding.
- You must not be a vehicle driver, machine operator, or pilot while on the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if certain natural compounds found in food can improve digestive health in adults with diarrhea-predominant irritable bowel syndrome (IBS-D). If you have IBS-D and are between 18 and 60, you may be able to join.
This Phase 3 study compares ebastine and mebeverine to see which works better for people with IBS that is not constipation-predominant. If you have IBS symptoms without an underlying intestinal disease, you may be offered one of these medicines and monitored for symptom improvement.
This trial tests whether eluxadoline can reduce symptoms of IBS with diarrhea (IBS-D) in children ages 6 to 17. It also asks families to track symptoms with a daily diary to measure whether treatment helps over the study period.
This trial tests a supplement called Gelsectan to see if it reduces diarrhea and belly pain in people with diarrhea-predominant irritable bowel syndrome (IBS-D). It may help if you have loose, urgent stools more often than not.
This trial is testing if a dietary supplement can reduce symptoms of irritable bowel syndrome (IBS). You might qualify if you have been diagnosed with IBS, have moderate to severe symptoms, and are between 18 and 75 years old.
This trial tests whether an oral medicine (eluxadoline) can help children and teens with IBS-D, a condition that causes stomach pain and frequent loose stools. It’s a Phase 3 study, meaning it’s designed to confirm benefits and safety.
Hear when a new Irritable Bowel Syndrome - Diarrhoea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.